It was highlighted that TANs, but not circulating neutrophils, via the production of CCL2 and CCL17 and the recruitment of monocytes and Treg cells, were the cause of the refractoriness to sorafenib, the first line treatment for hepatocellular carcinomas (HCC) (102, 103). Here, CCL2 is linked to hepatocellular carcinoma.